Daghlas I, Gill D. Low-density lipoprotein cholesterol and lifespan: A Mendelian randomization study. Br J Clin Pharmacol. 2021;87(10):3916–24. https://doi.org/10.1111/bcp.14811.

Article  PubMed  CAS  Google Scholar 

Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631–9. https://doi.org/10.1016/j.jacc.2012.09.017.

Article  PubMed  CAS  Google Scholar 

Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019;321(4):364–73. https://doi.org/10.1001/jama.2018.20045.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Michael D. Shapiro D, MCR and Kenneth R. Feingold, MD. Monogenic Disorders Causing Hypobetalipoproteinemia. Endotext; 2024.

Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21(4):225–45. https://doi.org/10.1038/s41580-019-0190-7.

Article  PubMed  CAS  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143. https://doi.org/10.1161/CIR.0000000000000625.

Article  PubMed  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.

Article  Google Scholar 

Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74(7):667–73. https://doi.org/10.1016/0002-9149(94)90307-7.

Article  PubMed  CAS  Google Scholar 

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7. https://doi.org/10.1056/NEJM199511163332001.

Article  PubMed  CAS  Google Scholar 

Administration USFaD: Pravachol HIGHLIGHTS OF PRESCRIBING INFORMATION. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019898s062lbl.pdf (2011). Accessed 09–17–2024 2024.

Banga JD, Jacotot B, Pfister P, Mehra M. Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study. French-Dutch Fluvastatin Study Group. Am J Med. 1994;96(6A):87S-93S. https://doi.org/10.1016/0002-9343(94)90238-0.

Article  PubMed  CAS  Google Scholar 

Insull W Jr, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, et al. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med. 1994;154(21):2449–55.

Article  PubMed  Google Scholar 

Jacotot B, Banga JD, Waite R, Peters TK. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group. Am J Cardiol. 1995;76(2):41A-6A. https://doi.org/10.1016/s0002-9149(05)80015-3.

Article  PubMed  CAS  Google Scholar 

Koren MJ, Smith DG, Hunninghake DB, Davidson MH, McKenney JM, Weiss SR, et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998;14(1):59–70. https://doi.org/10.2165/00019053-199814010-00006.

Article  PubMed  CAS  Google Scholar 

Zavoral JH, Haggerty BJ, Winick AG, Bergmann SD. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor FLUENT Study Group Fluvastatin Long-Term Extension Trial. Am J Cardiol. 1995;76(2):37A-40A. https://doi.org/10.1016/s0002-9149(05)80014-1.

Article  PubMed  CAS  Google Scholar 

Dujovne CA, Davidson MH. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med. 1994;96(6A):37S-40S. https://doi.org/10.1016/0002-9343(94)90230-5.

Article  PubMed  CAS  Google Scholar 

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9.

Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther. 1996;18(5):853–63. https://doi.org/10.1016/s0149-2918(96)80045-2.

Article  PubMed  CAS  Google Scholar 

Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15(5):678–82. https://doi.org/10.1161/01.atv.15.5.678.

Article  PubMed  CAS  Google Scholar 

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–60. https://doi.org/10.1016/s0002-9149(03)00530-7.

Article  PubMed  CAS  Google Scholar 

Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clinical Lipidology. 2009;4(3):291–302. https://doi.org/10.2217/clp.09.20.

Article  CAS  Google Scholar 

Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201(2):345–52. https://doi.org/10.1016/j.atherosclerosis.2008.02.008.

Article  PubMed  CAS  Google Scholar 

Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009;25(11):2755–64. https://doi.org/10.1185/03007990903290886.

Article  PubMed  CAS  Google Scholar 

Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014;36(8):1211–22. https://doi.org/10.1016/j.clinthera.2014.06.009.

Article  PubMed  CAS  Google Scholar 

Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18–28. https://doi.org/10.1016/j.ahj.2018.12.007.

Article  PubMed  CAS  Google Scholar 

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22. https://doi.org/10.1001/jama.279.20.1615.

Article  PubMed  CAS  Google Scholar 

Administration USFaD: Lescol HIGHLIGHTS OF PRESCRIBING INFORMATION. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020261s052,021192s026lbl.pdf (2005). Accessed September 19, 2024 2024.

Moroi M, Nagayama D, Hara F, Saiki A, Shimizu K, Takahashi M, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol. 2020;305:139–46. https://doi.org/10.1016/j.ijcard.2020.01.006.

Article  PubMed  Google Scholar 

Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22. https://doi.org/10.1016/S0140-6736(02)09327-3.

Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–16. https://doi.org/10.1016/s0140-6736(03)13636-7.

Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58. https://doi.org/10.1016/S0140-6736(03)12948-0.

Article  PubMed  CAS